Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][4] Presentation Details - Jasper will present five posters and one oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting from February 28 to March 3, 2025, in San Diego, CA [1] - The oral presentation titled "Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)" is scheduled for March 1, 2025, at 2:55 p.m. PST [2] - Additional poster presentations will cover various aspects of briquilimab's effects, including its ability to induce mast cell depletion and inhibit SCF/c-Kit signaling [2] Mechanism of Action - Briquilimab is an aglycosylated monoclonal antibody that blocks stem cell factor from binding to c-Kit, disrupting survival signals and leading to mast cell depletion through apoptosis [3][4] - This mechanism addresses the underlying inflammatory response in mast cell driven diseases, potentially offering therapeutic benefits for patients with CSU, CIndU, and asthma [4]